Randox Labs unveils ‘All in One’ COVID-19 diagnostic analyser
Randox Laboratories has unveiled Randox Discovery, a revolutionary COVID-19 diagnostic analyser. The benchtop laboratory for molecular and immunoassay diagnostics is the first of its kind to combine sample preparation techniques and Biochip Technology – a patented multiplex testing platform – in one high throughput fully-automated analyser.
Randox’s patented Biochip Technology allows simultaneous detection of hundreds of targets from a single sample. The technology is capable of detecting SARS-CoV-2 and differentiating between other respiratory pathogens with similar symptoms. It can detect all known strains of coronavirus comprising SARS-CoV-2, Sarbecovirus (SARS, SARS-like & SARS-CoV-2), coronavirus 229E, coronavirus NL63, coronavirus OC43 and coronavirus HKUI.
The combination of both SARS-CoV-2 and Sarbecovirus on the panel provides added confidence in patient diagnosis and helps to reduce false positives or negatives. This ultimately enables better treatment decisions and allows for more effective isolation and de-isolation of suspected and confirmed cases.
The Discovery has a rapid turnaround time with three hours to first batch of results and results for subsequent batches every hour after.
It is fully automated enabling a single operator to run up to 3 Discovery analysers.
For more information, visit: www.randox.com/randox-discovery/
Supplier: Randox Laboratories Ltd.
Website: http://www.randox.com/randox-discovery/
